Recombinant GM-CSF reduces lung injury and mortality during neutropenic Candida sepsis
- PMID: 8203549
- DOI: 10.1152/ajplung.1994.266.5.L561
Recombinant GM-CSF reduces lung injury and mortality during neutropenic Candida sepsis
Abstract
Cyclophosphamide (CY)-induced neutropenia exacerbates septic shock and acute lung injury during Candida albicans (CA) fungemia in conscious rats. We hypothesized that treatment of such animals with recombinant murine granulocyte-macrophage colony-stimulating factor (GM-CSF) improves host defense during disseminated candidiasis by increasing peripheral neutrophils (PMNs) and enhancing endogenous production of antifungal cytokines including tumor necrosis factor-alpha (TNF). Naive (neutrophil-replete) or neutropenic rats were infected with 10(7) yeast-phase CA; subgroups received GM-CSF (25 micrograms/kg sc) or sterile 0.9% NaCl (NS) twice a day beginning 3 days before CA infection. Arterial hemodynamics, formed blood elements, bioactive TNF in serum and bronchoalveolar lavage fluid (BALF), and lung histopathology were monitored for up to 72 h after infection. All naive animals receiving GM-CSF (n = 5) and 78% of naive rats given NS (n = 9) remained normotensive through 72 h with no lung injury, differing principally in baseline PMNs before CA infection (8.8 +/- 1.8 x 10(3)/microliters, mean +/- SE, vs. 3.7 +/- 0.4 x 10(3)/microliters, respectively, P < 0.01). Neutropenic rats given NS (baseline PMN = 41 +/- 10/microliters, n = 7) were sensitized to CA, and 100% died of hypothermic shock with severe respiratory distress within 56 h of infection. Pulmonary periarterial and alveolar hemorrhage were prominent. Although GM-CSF did not increase baseline PMNs in CY animals by the outset of infection (162 +/- 58/microliters, n = 8), 62% of these rats remained normotensive and eupneic through 72 h (P < 0.01), and their lungs showed no perivascular hemorrhage, alveolar disruption, or fungi.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Differential systemic and intrapulmonary TNF-alpha production in Candida sepsis during immunosuppression.Am J Physiol. 1992 Nov;263(5 Pt 1):L526-35. doi: 10.1152/ajplung.1992.263.5.L526. Am J Physiol. 1992. PMID: 1443156
-
The yeast to hyphal transition following hematogenous candidiasis induces shock and organ injury independent of circulating tumor necrosis factor-alpha.Crit Care Med. 1997 Jan;25(1):111-20. doi: 10.1097/00003246-199701000-00022. Crit Care Med. 1997. PMID: 8989186
-
Acute lung injury during bacterial or fungal sepsis.Microsc Res Tech. 1993 Dec 1;26(5):444-56. doi: 10.1002/jemt.1070260512. Microsc Res Tech. 1993. PMID: 8286790
-
Modulation of neutrophil function in host defense against disseminated Candida albicans infection in mice.FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):299-307. doi: 10.1111/j.1574-695X.1999.tb01402.x. FEMS Immunol Med Microbiol. 1999. PMID: 10575142 Review.
-
Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis.Bone Marrow Transplant. 1996 Jul;18(1):93-102. Bone Marrow Transplant. 1996. PMID: 8832001 Review.
Cited by
-
Nonventilatory treatments for acute lung injury and ARDS.Chest. 2007 Mar;131(3):913-920. doi: 10.1378/chest.06-1743. Chest. 2007. PMID: 17356114 Free PMC article. Review.
-
The Pathophysiology and Treatment of Candida Sepsis.Curr Infect Dis Rep. 2002 Oct;4(5):387-399. doi: 10.1007/s11908-002-0005-3. Curr Infect Dis Rep. 2002. PMID: 12228025
-
Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis?Intensive Care Med. 2003 Aug;29(8):1245-52. doi: 10.1007/s00134-003-1686-2. Epub 2003 May 28. Intensive Care Med. 2003. PMID: 12774155 Clinical Trial.
-
Hematopoietic growth factors in cancer patients with invasive fungal infections.Eur J Clin Microbiol Infect Dis. 1997 Jan;16(1):56-63. doi: 10.1007/BF01575122. Eur J Clin Microbiol Infect Dis. 1997. PMID: 9063675 Review.
-
Novel GM-CSF signals via IFN-γR/IRF-1 and AKT/mTOR license monocytes for suppressor function.Blood Adv. 2017 Jun 7;1(14):947-960. doi: 10.1182/bloodadvances.2017006858. eCollection 2017 Jun 13. Blood Adv. 2017. PMID: 29296736 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous